Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | PREP | P48147 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.31 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2827455 | 0.78 | TP53 (0.40) | TP53POLBMAPTKDM4EMEN1 | |
| SCHEMBL11437996 | 0.71 | TP53 (0.39) | TP53POLBMAPTKDM4EMEN1 | |
| SCHEMBL3174521 | 0.71 | TP53 (0.34) | TP53POLBMAPTKDM4EMEN1 | |
| SCHEMBL2600449 | 0.71 | TP53 (0.34) | TP53POLBMAPTKDM4EMEN1 | |
| SCHEMBL30556213 | 0.69 | CA1 (0.38) | TP53CA12CA1CA9PREP | |
| Water SCHEMBL5362631 | 0.68 | POLB (0.32) | TP53POLBMAPTKDM4EMEN1 | |
| SCHEMBL6763899 | 0.67 | PREP (0.53) | CA12CA1CA9PREPKDM4E | |
| SCHEMBL827212 | 0.67 | — | — | |
| SCHEMBL4438037 | 0.67 | ALDH1A1 (0.44) | CA12CA1CA9PREPPOLB | |
| SCHEMBL2368966 | 0.67 | PREP (0.45) | CA12CA1CA9PREPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4237057-A | KALAFUNGIN AND 9-DEOXYKALAFUNGIN | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1980-12-02 | — | — | US | claimed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| CN-116670143-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| US-9314782-B2 | Bis(trifluoromethanesulfonyl)ethyl-bearing compound and acid catalyst, and method for preparing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2016-04-19 | — | — | US | disclosed |
| US-9314782-B2 | Bis(trifluoromethanesulfonyl)ethyl-bearing compound and acid catalyst, and method for preparing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20140066659-A1 | Bis(Trifluoromethanesulfonyl)Ethyl-Bearing Compound and Acid Catalyst, and Method for Preparing Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| US-20140066659-A1 | Bis(Trifluoromethanesulfonyl)Ethyl-Bearing Compound and Acid Catalyst, and Method for Preparing Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| US-6649626-B1 | Stimulants of gamma -aminobutyric acid receptors; psychological disorders | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2003-11-18 | — | — | US | disclosed |
| EP-1224182-B1 | N-SUBSTITUTED 1-(BUTYROLACTONE)-ISOQUINOLINES FOR TREATING NERVOUS DISORDERS | CENTRE NAT RECH SCIENT (FR) | 2003-07-16 | — | — | EP | disclosed |
| EP-1224182-A1 | N-SUBSTITUTED 1-(BUTYROLACTONE)-ISOQUINOLINES FOR TREATING NERVOUS DISORDERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001029030-A1 | N-SUBSTITUTED 1-(LACTONE) ISOQUINOLONES FOR TREATING NERVOUS DISORDERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | TP53 2778/4885CA12 4587/4885CA1 4871/4885 |
| US-20140066659-A1 | Bis(Trifluoromethanesulfonyl)Ethyl-Bearing Compound and Acid Catalyst, and Method for Preparing Same | FOS, ETV6, ABL1 | TP53 1120/4885CA12 1069/4885CA1 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.